ALVO -
Alvotech Ordinary Shares
| Day |
1m |
10m |
60m |
PreMarket |
Market |
AfterHours |
Gap |
| 5.11 0.06 (1.21%) |
0.0 (0.0%) |
0.0 (0.0%) |
-0.05 (-1.02%) |
0.01 (0.2%) |
0.05 (1.01%) |
0.0 (0.0%) |
-0.06 (-1.16%) |
Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Earnings & Ratios
- Basic EPS:
- Diluted EPS:
- Basic P/E:
- Diluted P/E:
- RSI(14) 1m:
- 82.42
- VWAP:
- 5.17
- RVol:
Events
| Period |
Kind |
Movement |
Occurred At |
Related News
Bragar Eagel & Squire, P.C. Continues Investigations into Regencell, Beyond Meat, Alvotech, and Camping World on Behalf of Stockholders and Encourages Investors to Contact the Firm
Nov 22, 2025 16:04
Alvotech (ALVO) Faces Investor Scrutiny Amid Manufacturing Deficiencies Severely Impacting Assurances of 2025 Revenues and Adjusted EBITDA, Stock Tumbles 33% -- Hagens Berman
Nov 19, 2025 19:58
Scott+Scott Attorneys at Law LLP Alerts Investors of Its Investigation into Alvotech (NASDAQ: ALVO)
Nov 06, 2025 23:28
Alvotech og Advanz Pharma fá markaðsleyfi í Bretlandi fyrir Gobivaz, hliðstæðu við Simponi (golimumab)
Nov 06, 2025 14:00
Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
Nov 06, 2025 14:00
Alvotech Shares Plunge 33% After FDA Flags Issues
Nov 03, 2025 18:17
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
Nov 02, 2025 22:12
Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
Nov 02, 2025 22:10
Alvotech birtir nýjar upplýsingar um stöðu umsóknar um markaðsleyfi fyrir AVT05 í Bandaríkjunum
Nov 02, 2025 22:10
Alvotech Announces Changes in Global Business Development and Commercial Operations Team
Oct 22, 2025 09:00